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Abstract 
Background: The aim of this study was to investigate the expression and clinical implications of proteins related to 
serine/glycine metabolism in different subtypes of thyroid cancer.
Methods: Tissue microarray (TMA) was constructed with tissues from 557 thyroid cancers, consisting of 244 papillary 
thyroid carcinomas (PTC), 112 follicular carcinomas (FC), 70 medullary carcinomas (MC), 23 poorly differentiated car‑
cinomas (PDC), and 8 anaplastic carcinomas (AC). Immunohistochemical staining of the serine/glycine metabolism‑
related molecules phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase, (PSAT), phosphoser‑
ine phosphatase (PSPH), serine hydromethyl transferase (SHMT), and glycine decarboxylase (GLDC) was performed 
with the TMA blocks and the results were analyzed together with clinicopathologic parameters.
Results: The expression of serine/glycine metabolism‑related proteins differed among thyroid cancer subtypes. The 
expression rate of PHGDH (p < 0.001), PSAT1 (p = 0.001), PSPH (p = 0.008), and tumoral SHMT1 (p < 0.001) was higher 
in PDC and PTC (78.3, 21.7, 21.7, 30.4 and 63.4, 18.6, 12.8, 31.4 %, respectively), and lowest in MC (15.7, 1.4, 0.0, 10.0 %). 
Stromal SHMT1 expression was highest in AC (62.5 %) and absent in all FC (p < 0.001). In PTC, positivity for PSPH 
(p = 0.041), tumoral SHMT1 (p = 0.018), and stromal SHMT1 (p < 0.001) expression was higher in the conventional 
type compared to follicular type (14.1 versus 2.5 %, 33.6 versus 15.0 %, 42.1 versus 10.0 %, respectively). BRAF V600E 
mutation was associated with a higher rate of PHGDH (p < 0.001), PSAT1 (p = 0.001), PSPH (p < 0.001), tumoral SHMT1 
(p = 0.001), stromal SHMT1 (p < 0.001), and GLDC (p < 0.001) expression compared to non‑mutant cases (73.5 versus 
40.6 %, 23.1 versus 8.5 %, 17.6 versus 1.9 %, 37.0 versus 18.9 %, 45.8 versus 21.7 %, 21.8 versus 6.6 %, respectively). In 
univariate analysis, stromal SHMT1 expression was associated with shorter disease‑free survival (p = 0.015) in follicular 
variant PTC, and GLDC positivity was associated with shorter overall survival (OS) in sclerotic stromal type (p = 0.002). 
In FC, minimally invasive type, PSPH positivity correlated with shorter OS (p = 0.045) and in MC, PHGDH positivity cor‑
related with shorter OS (p = 0.034).
Conclusion: The expression of serine/glycine metabolism‑related proteins differs among different thyroid cancer 
types, with a higher rate of expression in PDC and PTC, and lower rate of expression in MC. In PTC, the rate of expres‑
sion is lower in the follicular variant and higher in cases with BRAF V600E mutation.
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Background
In malignant neoplasms a metabolic shift from oxidative 
phosphorylation in mitochondria to glycolysis occurs, a 
phenomenon known as the Warburg effect [1]. Neoplas-
tic cells exhibiting increased glycolysis show increased 
levels of glycolytic intermediates. Recent studies reported 
that the metabolism of glycolytic intermediates is 
involved in tumorigenesis, for example through the gly-
cine and serine metabolic pathways [2–5]. In the serine 
biosynthesis pathway, the 3-phosphoglycerate (3PG) 
that is generated in the glycolysis process is oxidized to 
3-phosphohydroxypyruvate (pPYR) by phosphoglycer-
ate dehydrogenase (PHGDH) [6]. pPYR is transaminated 
into phosphoserine (pSER) by phosphoserine ami-
notransferase (PSAT) [7], and pSER is dephosphorylated 
by phosphoserine phosphatase (PSPH) to produce serine 
[8]. In glycine metabolism, methylene-tetrahydrofolate 
is generated by glycine decarboxylase (GLDC), using 
glycine and tetrahydrofolate as substrates [9]. Serine 
metabolism and glycine metabolism are linked by ser-
ine hydromethyl transferase (SHMT), which catalyzes 
the reversible conversion of serine and glycine [10]. In 
previous studies, expression of PHGDH was reported to 
be increased in breast cancer and melanoma [3, 4], and 
expression of GLDC was reported to be increased in lung 
cancer [5], revealing a role of proteins related to serine/
glycine metabolism in tumorigenesis.
Thyroid cancer is a common malignant neoplasm that 
occurs in 1 % of the population [11]. The most common 
subtype is papillary thyroid carcinoma (PTC), although 
there are several other subtypes, including follicular 
carcinoma (FC), medullary carcinoma (MC), poorly dif-
ferentiated carcinoma (PDC), and anaplastic carcinoma 
(AC). These subtypes differ in cell origin, clinical mani-
festation, metastatic pattern, and clinical prognosis [12].
A representative mutation gene in thyroid cancer is the 
BRAF mutation gene. BRAF is a 75–100 kDa protein in 
the Raf kinase family that is the most potent activator of 
MEK kinase in the Ras-Raf-MEK-ERK pathway [2, 5]. 
The Ras-Raf-MEK-ERK pathway is abnormally activated 
in tumors and this aberrant ERK signaling is due to the 
BRAF mutation [4]. The BRAF mutation first reported in 
2002 is a mutation in nucleotide 1796 in about 90 % that 
converts valine to glutamic acid in codon 599 (V599E; 
After NOMENCLATURE CHANGE, it was renamed 
to V600E) [13]. The BRAF V600E mutation appears in 
a variety of tumors found in cancers including thyroid 
papillary carcinoma (36–53  %), malignant melanoma 
(40–70 %), colorectal carcinoma (5–22 %), glioma (11 %), 
and ovary serous carcinoma (30 %) [3]. The BRAF muta-
tion in PTC is associated with extra-thyroidal extension, 
advanced TNM stage, lymph node metastasis, multifo-
cality, and recurrence [14].
It is thought that tumor metabolism, including serine 
and glycine metabolism, may differ among these sub-
types, however there are few reports on this subject. The 
aim of this study was to investigate the expression and 
clinical implications of proteins related to serine/glycine 
metabolism according to thyroid cancer subtype.
Methods
Patient selection
Patients who were diagnosed with PTC and had surgi-
cal resection from January 2012 to December 2013 were 
enrolled in this study. Patients who were diagnosed with 
other subtypes of thyroid cancer from January 2000 to 
December 2014 were also enrolled. Patients who received 
preoperative chemotherapy were excluded. A thyroid 
pathologist (Koo JS) reviewed hematoxylin/eosin (H&E)-
stained slides for all cases. Clinicopathologic data were 
obtained from the patients’ medical records and included 
age at diagnosis, disease recurrence, metastasis, current 
status, and length of follow-up. Tumor size, location 
(right or left lobe), extent (confined to the thyroid paren-
chyme or with extrathyroidal spread), and number of 
metastatic lymph nodes were also noted from review of 
the slides and the surgical pathology reports.
Tissue microarray (TMA)
Representative areas were selected on H&E-stained slides 
and corresponding spots were marked on the surface of 
the matching paraffin blocks. Five-mm core biopsies were 
taken from selected areas and placed into a 5 × 4 recipi-
ent block. More than two tissue cores were extracted 
from each case to minimize extraction bias. Each tissue 
core was assigned a unique tissue microarray location 
number that was linked to a database containing other 
clinicopathologic data.
Immunohistochemistry
Antibodies used for immunohistochemistry are listed in 
Additional file  1: Table S1. All immunohistochemistry 
was performed with formalin-fixed paraffin-embedded 
tissue sections using an automatic immunohistochem-
istry staining device (Benchmark XT, Ventana Medical 
System, Tucson, AZ, USA). Briefly, 5-µm thick formal-
dehyde-fixed paraffin-embedded tissue sections were 
transferred onto adhesive slides and dried at 62  °C for 
30  min. Standard heat epitope retrieval was performed 
for 30  min in ethylene diaminetetraacetic acid, pH 8.0, 
in the autostainer. The samples were then incubated 
sequentially with primary antibodies, biotinylated anti-
mouse immunoglobulin, peroxidase-labeled streptavidin 
(LSAB kit, DakoCytomation), and 3,30-diaminobenzi-
dine. Negative control samples were processed without 
the primary antibody. Slides were counterstained with 
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Harris hematoxylin. Positive control tissue was used as 
recommended by the manufacturer.
Analysis of immunohistochemical staining
This study used the semi-quantitative ordinal scoring sys-
tem based on visual inspection by pathologists. Immuno-
histochemical markers were assessed by light microscopy. 
The expression of serine/glycine metabolism-related 
proteins was evaluated semi-quantitatively as previ-
ously reported [15]. Tumor and stromal cell staining was 
scored as follows: 0, negative or weak immunostaining in 
<1 % of the tumor/stroma; 1, focal expression in 1–10 % 
of tumor/stroma; 2, positive in 11–50 % of tumor/stroma; 
3, positive in 51–100 % of tumor/stroma. The evaluation 
was performed throughout the whole area of the tumor, 
and a score of 2 or higher was defined as positive. For 
the evaluation of BRAF V600E, tissue samples that had 
scores of 20 % or higher were regarded as positive [16]. 
Two pathologists (KJS and KHM) independently evalu-
ated the expression according the scoring system and 
any mismatched result was further evaluated by a third 
pathologist (JW).
Statistical analysis
Data were analyzed using SPSS for Windows, Version 
12.0 (SPSS Inc., Chicago, IL, USA). For determina-
tion of statistical significance, Student’s t and Fisher’s 
exact tests were used for continuous and categorical 
variables, respectively. In the case of multiple com-
parisons, a corrected p value with the application 
of the Bonferroni multiple comparison procedure 
was used. Statistical significance was set to p < 0.05. 
Kaplan–Meier survival curves and log-rank statistics 
were employed to evaluate time to tumor recurrence 
and overall survival. Multivariate regression analysis 
was performed using the Cox proportional hazards 
model.
Results
Basal characteristics of thyroid cancer
Among 557 thyroid cancers, 344 (61.8  %) were PTC, 
112 (20.1  %) were FC, 70 (12.6  %) were MC, 23 (4.1  %) 
were PDC, and 8 (1.4 %) were AC. Basal characteristics 
of PTC are summarized in Additional file  1: Table S2. 
PTC cases consisted of 304 (88.4  %) cases of conven-
tional type and 40 (11.6  %) cases of follicular variant. 
Follicular variant PTC had a higher rate of expanding 
tumor margin (p =  0.002) than conventional type (32.5 
versus 13.8  %). BRAF V600E mutation was present in 
238 of PTCs (69.2 %) and was associated with an infiltra-
tive tumor margin (87.8 %, p = 0.004) and conventional 
type (93.7 %, p < 0.001, Additional file 1: Table S2). The 
rate of follicular variant was only 6.3  % among cases 
with BRAF V600E. Follicular carcinoma consisted of 99 
(88.4 %) cases of minimally invasive type and 13 (11.6 %) 
cases of widely invasive type, and the widely invasive 
type was associated with larger tumor size (>2.0 cm 100 
versus 65.7 %, p = 0.040), vascular invasion (69.2 versus 
37.4 %, p = 0.028), extrathyroidal involvement (53.8 ver-
sus 10.1 %, p < 0.001), and distant metastasis (38.5 versus 
6.1  %, p  =  0.003) compared to minimally invasive type 
(Additional file 1: Table S3). Basal characteristics of MC, 
PDC, and AC are summarized in Additional file 1: Table 
S4.
Expression of serine/glycine metabolism‑related proteins 
in thyroid cancer subtypes
The expression of serine/glycine metabolism-related 
proteins was investigated in all thyroid cancers. For the 
serine/glycine metabolism-related proteins, PHGDH had 
the highest expression rate (54.8  %) compared to lower 
expression rates of stromal SHMT1 (25.9  %), tumoral 
SHMT1 (25.5  %), GLDC (15.6  %), PSAT1 (14.4  %), and 
PSPH (10.8  %). Therefore, serine/glycine metabolism-
related protein expression rate was low in most cases 
except for PHGDH (Table 1). The expression of PHGDH 
(p  <  0.001), PSAT1 (p  =  0.001), PSPH (p  =  0.008), 
tumoral SHMT1 (p  <  0.001), and stromal SHMT1 
(p  <  0.001) was different according to cancer subtype 
(Fig. 1a). The expression of PHGDH, PSAT1, PSPH, and 
tumoral SHMT1 was higher in PDC and PTC (78.3, 21.7, 
21.7, 30.4 and 63.4, 18.6, 12.8, 31.4 %, respectively), and 
lowest in MC (15.7, 1.4, 0.0, 10.0  %). The expression of 
stromal SHMT1 was highest in AC (62.5 %) and lowest in 
FC (0.0 %) (Table 1; Fig. 2).
Among PTCs, the expression of PSPH (p  =  0.041), 
tumoral SHMT1 (p  =  0.018), and stromal SHMT1 
(p  <  0.001) differed according to histologic subtypes, 
with a higher rate of expression in the conventional type 
compared to follicular type (14.1 versus 2.5 %, 33.6 versus 
15.0 %, 42.1 versus 10.0 %, respectively) (Table 2; Fig. 1b). 
BRAF V600E mutation status was associated with the 
expression of PHGDH (p  <  0.001), PSAT1 (p  =  0.001), 
PSPH (p < 0.001), tumoral SHMT1 (p = 0.001), stromal 
SHMT1 (p < 0.001), and GLDC (p < 0.001), with higher 
expression of serine/glycine metabolism-related proteins 
in BRAF V600E mutation-positive cases compared to 
non-mutant cases (73.5 versus 40.6 %, 23.1 versus 8.5 %, 
17.6 versus 1.9 %, 37.0 versus 18.9 %, 45.8 versus 21.7 %, 
21.8 versus 6.6 %, respectively) (Table 2; Fig. 3).
Among follicular neoplasms, the expression of PSAT1 
was higher in follicular adenoma compared to FC (24.2 
versus 8.0 %, p = 0.001, Table 3). There was no difference 
in serine/glycine metabolism-related protein expression 
between the minimally invasive and widely invasive type 
of FC (Table 4).
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Correlation between the expression of serine/glycine 
metabolism‑related proteins and clinicopathologic factors
Correlations between the expression of serine/glycine 
metabolism-related proteins and clinicopathologic factors 
of thyroid cancers were analyzed. In PTC, PHGDH expres-
sion was associated with tumor size (p =  0.003), with an 
increased tumor size in PHGDH-positive cases. In addition, 
stromal histologic type of PTC was associated with PHGDH 
(p  =  0.006), tumoral SHMT1 (p  =  0.005), and stromal 
SHMT1 (p < 0.001) expression. Inflammatory type showed 
a lower rate of PHGDH expression compared to other sub-
types, and desmoplastic type and inflammatory type had a 
higher rate of tumoral and stromal SHMT1 expression com-
pared to pauci type and sclerotic type (Fig. 4).
Table 1 Expression of serine/glycine metabolism-related proteins according to the subtype of thyroid cancer
PTC papillary thyroid carcinoma; FC follicular carcinoma; MC medullary carcinoma; PDC poorly differentiated carcinoma; AC anaplastic carcinoma; PHGDH 
phosphoglycerate dehydrogenase; PSAT phosphoserine aminotransferase; PSPH phosphoserine phosphatase; SHMT serine hydromethyl transferase; GLDC glycine 
decarboxylase
Italic values represent p < 0.05
Parameters Total n = 557 (%) PTC n = 344 (%) FC n = 112 (%) MC n = 70 (%) PDC n = 23 (%) AC n = 8 (%) P value
PHGDH in tumor <0.001
 Negative 252 (45.2) 126 (36.6) 58 (51.8) 59 (84.3) 5 (21.7) 4 (50.0)
 Positive 305 (54.8) 218 (63.4) 54 (48.2) 11 (15.7) 18 (78.3) 4 (50.0)
PSAT1 in tumor 0.001
 Negative 477 (85.6) 280 (81.4) 103 (92.0) 69 (98.6) 18 (78.3) 7 (87.5)
 Positive 80 (14.4) 64 (18.6) 9 (8.0) 1 (1.4) 5 (21.7) 1 (12.5)
PSPH in tumor 0.008
 Negative 497 (89.2) 300 (87.2) 101 (90.2) 70 (100.0) 18 (78.3) 8 (100.0)
 Positive 60 (10.8) 44 (12.8) 11 (9.8) 0 (0.0) 5 (21.7) 0 (0.0)
SHMT1 in tumor <0.001
 Negative 415 (74.5) 236 (68.6) 94 (83.9) 63 (90.0) 16 (69.6) 6 (75.0)
 Positive 142 (25.5) 108 (31.4) 18 (16.1) 7 (10.0) 7 (30.4) 2 (25.0)
SHMT1 in stroma <0.001
 Negative 413 (74.1) 212 (61.6) 112 (100.0) 65 (92.9) 21 (91.3) 3 (37.5)
 Positive 144 (25.9) 132 (38.4) 0 (0.0) 5 (7.1) 2 (8.7) 5 (62.5)
GLDC in tumor 0.529
 Negative 470 (84.4) 285 (82.8) 96 (85.7) 60 (85.7) 21 (91.3) 8 (100.0)
 Positive 87 (15.6) 59 (17.2) 16 (14.3) 10 (14.3) 2 (8.7) 0 (0.0)
Fig. 1 Heat map of expression of serine/glycine metabolism‑related proteins in thyroid cancer (a) and papillary thyroid cancer (b). Red, positive; 
green, negative, PTC papillary thyroid carcinoma; FC follicular carcinoma; MC medullary carcinoma; PDC poorly differentiated carcinoma; AC anaplas‑
tic carcinoma; PHGDH phosphoglycerate dehydrogenase; PSAT phosphoserine aminotransferase; PSPH phosphoserine phosphatase; SHMT serine 
hydromethyl transferase; GLDC glycine decarboxylase; S stroma
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Impact of the expression of serine/glycine 
metabolism‑related proteins on patient prognosis
In analysis of the impact of the expression of serine/
glycine metabolism-related proteins on patient progno-
sis, the expression of serine/glycine metabolism-related 
proteins did not have an association with prognosis for 
overall PTC (Table  5). However, for follicular variant 
PTC the expression of stromal SHMT1 was associated 
with shorter disease-free survival (DFS; p = 0.015), and 
in the sclerotic stromal type, GLDC positivity was associ-
ated with shorter overall survival (OS; p = 0.002). PSPH 
positivity was associated with shorter OS in minimally 
invasive type FC (p = 0.045) and PHGDH positivity cor-
related with shorter OS in MC (p = 0.034, and Fig. 5).
Fig. 2 Expression of serine/glycine metabolism‑related proteins in thyroid cancer. The expression of PHGDH, PSAT1, PSPH, tumoral SHMT1, and 
stromal SHMT1 is different according to cancer subtype. The expression of PHGDH, PSAT1, PSPH, and tumoral SHMT1 is higher in PDC and PTC, and 
lowest in MC. The expression of stromal SHMT1 is highest in AC and lowest in FC
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Discussion
In this study, we investigated the expression of pro-
teins related to serine/glycine metabolism in thyroid 
cancers and found differences in expression accord-
ing to the different types of thyroid cancer. In general, 
the rate of serine/glycine metabolism-related protein 
expression was higher in PDC and PTC, and lower in 
MC. As there are no previous studies regarding serine/
glycine metabolism in thyroid cancer a direct com-
parison cannot be made, however MC is a tumor that 
originates from C-cells whereas other thyroid neo-
plasms originate from follicular cells, so they might 
be expected to have different metabolic features. The 
results of our study suggest that C-cell origin MC may 
have lower serine/glycine metabolic activity, although 
further study is required to examine this finding. The 
Table 2 Expression of glutamine metabolism-related proteins according to the histologic subtype of PTC
PTC papillary thyroid carcinoma; PHGDH phosphoglycerate dehydrogenase; PSAT phosphoserine aminotransferase; PSPH phosphoserine phosphatase; SHMT serine 
hydromethyl transferase; GLDC glycine decarboxylase
Italic values represent p < 0.05
Parameters Total  
n = 344 (%)









PHGDH in tumor 0.564 <0.001
 Negative 126 (36.6) 113 (37.2) 13 (32.5) 63 (59.4) 63 (26.5)
 Positive 218 (63.4) 191 (62.8) 27 (67.5) 43 (40.6) 175 (73.5)
PSAT1 in tumor 0.501 0.001
 Negative 280 (81.4) 249 (81.9) 31 (77.5) 97 (91.5) 183 (76.9)
 Positive 64 (18.6) 55 (18.1) 9 (22.5) 9 (8.5) 55 (23.1)
PSPH in tumor 0.041 <0.001
 Negative 300 (87.2) 261 (85.9) 39 (97.5) 104 (98.1) 196 (82.4)
 Positive 44 (12.8) 43 (14.1) 1 (2.5) 2 (1.9) 42 (17.6)
SHMT1 in tumor 0.018 0.001
 Negative 236 (68.6) 202 (66.4) 34 (85.0) 86 (81.1) 150 (63.0)
 Positive 108 (31.4) 102 (33.6) 6 (15.0) 20 (18.9) 88 (37.0)
SHMT1 in stroma <0.001 <0.001
 Negative 212 (61.6) 176 (57.9) 36 (90.0) 83 (78.3) 129 (54.2)
 Positive 132 (38.4) 128 (42.1) 4 (10.0) 23 (21.7) 109 (45.8)
GLDC in tumor 0.116 <0.001
 Negative 285 (82.8) 248 (81.6) 37 (92.5) 99 (93.4) 186 (78.2)
 Positive 59 (17.2) 56 (18.4) 3 (7.5) 7 (6.6) 52 (21.8)
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present study showed that stromal SHMT1 expression 
was highest in AC. In previous studies of breast can-
cer, it was reported that serine/glycine metabolism-
related proteins were expressed not only in tumor cells 
but also in stromal cells [17, 18]. Moreover, glycolysis 
[19–21] and glutamine metabolism were reported to 
mediate metabolic interactions between cancer cells 
and stromal cells such as cancer-associated fibroblasts 
(CAFs) [20, 22–25]. Metabolic interactions between 
cancer cells and CAFs promote tumor cell proliferation 
and growth, suggesting that serine/glycine metabolic 
activity in both tumor and stroma contributes to tumor 
aggressiveness in AC.
We observed a higher rate of serine/glycine metab-
olism-related protein expression in cases of PTC with 
the BRAF V600E mutation. In meta-analysis studies, 
the BRAF V600E mutation is reported to be associ-
ated with extra-thyroidal extension, advanced TNM 
stage, lymph node metastasis, multifocality, and 
recurrence [14], suggesting that PTC with a BRAF 
V600E mutation has more aggressive tumor biol-
ogy. In general, higher metabolic activity is related to 
increased tumor aggressiveness [26–28], and higher 
expression levels of proteins related to serine/glycine 
metabolism might be expected in BRAF V600E-pos-
itive cases. In addition, PTC with the BRAF V600E 
mutation is reported to have enhanced glucose 
metabolism [29]. Since serine metabolism initiates 
from 3PG, which is generated in the glycolysis path-
way, increased serine metabolism might be expected 
when glycolysis is increased.
A clinical implication of this study is the potential 
application of targeted therapy against the serine/
glycine metabolism pathway. Preclinical studies are 
ongoing to identify drugs that target multiple sites of 
one-carbon metabolism, such as GLDC, PSAT, PSPH, 
and PHGDH, as a novel therapeutic approach [30, 
31].
Conclusion
The expression of serine/glycine metabolism-related pro-
teins differs among different thyroid cancer types, with a 
higher rate of expression in PDC and PTC, and a lower 
rate of expression in MC. In PTC, the rate of serine/gly-
cine metabolism-related protein expression is lower in 
the follicular variant, and higher in cases with the BRAF 
V600E mutation.
Fig. 3 Expression of serine/glycine metabolism‑related proteins 
according to the status of BRAF V600E mutation in papillary carci‑
noma. BRAF V600E mutation status was associated with the expres‑
sion of PHGDH, PSAT1, PSPH, tumoral SHMT1, stromal SHMT1, and 
GLDC, with higher expression of serine/glycine metabolism‑related 
proteins in BRAF V600E mutation‑positive cases
Page 8 of 12Sun et al. J Transl Med  (2016) 14:168 
Table 3 Expression of serine/glycine metabolism-related proteins in follicular neoplasm
PHGDH phosphoglycerate dehydrogenase; PSAT phosphoserine aminotransferase; PSPH phosphoserine phosphatase; SHMT serine hydromethyl transferase; GLDC 
glycine decarboxylase
Italic value represents p < 0.05
Parameters Total n = 264 (%) Follicular adenoma  
n = 152 (%)
Follicular carcinoma  
n = 112 (%)
p value
PHGDH in tumor 0.274
 Negative 147 (55.7) 89 (58.6) 58 (51.8)
 Positive 117 (44.3) 63 (41.4) 54 (48.2)
PSAT1 in tumor 0.001
 Negative 219 (82.6) 116 (75.8) 103 (92.0)
 Positive 46 (17.4) 37 (24.2) 9 (8.0)
PSPH in tumor 0.328
 Negative 244 (92.1) 143 (93.5) 101 (90.2)
 Positive 21 (7.9) 10 (6.5) 11 (9.8)
SHMT1 in tumor 0.137
 Negative 211 (79.6) 117 (76.5) 94 (83.9)
 Positive 54 (20.4) 36 (23.5) 18 (16.1)
GLDC in tumor 0.262
 Negative 234 (88.3) 138 (90.2) 96 (85.7)
 Positive 31 (11.7) 15 (9.8) 16 (14.3)
Table 4 Expression of serine/glycine metabolism-related proteins according to the histologic subtype of follicular carci-
noma
PHGDH phosphoglycerate dehydrogenase; PSAT phosphoserine aminotransferase; PSPH phosphoserine phosphatase; SHMT serine hydromethyl transferase; GLDC 
glycine decarboxylase
Parameters Total n = 112 (%) FC, minimally invasive type  
n = 99 (%)
FC, widely invasive type  
n = 13 (%)
p value
PHGDH in tumor 0.454
 Negative 58 (51.8) 50 (50.5) 8 (61.5)
 Positive 54 (48.2) 49 (49.5) 5 (38.5)
PSAT1 in tumor 1.000
 Negative 103 (92.0) 91 (91.9) 12 (92.3)
 Positive 9 (8.0) 8 (8.1) 1 (7.7)
PSPH in tumor 0.357
 Negative 101 (90.2) 88 (88.9) 13 (100.0)
 Positive 11 (9.8) 11 (11.1) 0 (0.0)
SHMT1 in tumor 0.689
 Negative 94 (83.9) 82 (82.8) 12 (92.3)
 Positive 18 (16.1) 17 (17.2) 1 (7.7)
GLDC in tumor 1.000
 Negative 96 (85.7) 85 (85.9) 11 (84.6)
 Positive 16 (14.3) 14 (14.1) 2 (15.4)
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Fig. 4 Correlation between the expression of serine/glycine metabolism‑related proteins and clinicopathologic factors in papillary carcinoma. a In 
PTC, PHGDH expression is associated with tumor size, with an increased tumor size in PHGDH‑positive cases. b Inflammatory type shows a lower 
rate of PHGDH expression compared to other subtypes, and desmoplastic type and inflammatory type have a higher rate of tumoral (c) and stromal 
d SHMT1 expression compared to pauci type and sclerotic type
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Table 5 Univariate analysis of  the impact of  serine/glycine-related protein expression in  papillary thyroid carcinoma 
on disease-free and overall survival by the log-rank test
CI confidence interval; PHGDH phosphoglycerate dehydrogenase; PSAT phosphoserine aminotransferase; PSPH phosphoserine phosphatase; SHMT serine hydromethyl 
transferase; GLDC glycine decarboxylase
a Cases of anaplastic carcinoma were excluded
Parameter Number of patientsa/ 
recurrence/death
Disease‑free survival Overall survival
Mean survival  
(95 % CI) months
p value Mean survival  
(95 % CI) months
p value
PHGDH in tumor 0.790 0.806
 Negative 126/6/6 105 (101–108) 106 (103–109)
 Positive 218/12/12 106 (104–109) 107 (105–110)
PSAT1 in tumor 0.159 0.231
 Negative 280/17/13 106 (103–109) 108 (106–110)
 Positive 64/1/5 108 (105–111) 103 (97–108)
PSPH in tumor 0.606 0.221
 Negative 300/15/14 107 (105–109) 108 (106–110)
 Positive 44/3/4 103 (96–110) 103 (96–109)
SHMT1 in tumor 0.498 0.248
 Negative 236/11/10 107 (105–110) 108 (106–110)
 Positive 108/7/8 104 (100–109) 105 (101–109)
SHMT1 in stroma 0.655 0.684
 Negative 212/12/10 106 (103–109) 108 (106–110)
 Positive 132/6/8 107 (104–111) 107 (103–110)
GLDC in tumor 0.516 0.059
 Negative 285/14/12 107 (105–109) 108 (106–110)
 Positive 59/4/6 104 (97–110) 103 (97–109)
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Additional file 1: Table S1. Source, clone, and dilution of antibodies 
used in this study. Table S2. Basal characteristics of thyroid papillary 
carcinoma. Table S3. Basal characteristics of thyroid follicular carcinoma. 
Table S4. Basal characteristics of thyroid medullary carcinoma, poorly 
differentiated carcinoma, and anaplastic carcinoma.
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Fig. 5 Impact of the expression of serine/glycine metabolism‑related proteins on patient prognosis. a For follicular variant PTC, the expression 
of stromal SHMT1 is associated with shorter disease‑free survival. b In the sclerotic stromal type, GLDC positivity is associated with shorter overall 
survival. c PSPH positivity is associated with shorter OS in minimally invasive type FC. d PHGDH positivity correlated with shorter OS in MC
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